

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	CHANGE OF NAME		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Adams Laboratories, Inc.		04/18/2005	CORPORATION: TEXAS
RECEIVING PARTY DATA			
Name:	Adams Respiratory Therapeutics, Inc.		
Street Address:	425 Main Street		
City:	Chester		
State/Country:	NEW JERSEY		
Postal Code:	07930		
Entity Type:	CORPORATION: TEXAS		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1361351	HUMIBID	
CORRESPONDENCE DATA			
Fax Number:	(813)314-5160		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	813-227-8500.		
Email:	karen.lee@hklaw.com		
Correspondent Name:	James B. Lake, Esq.		
Address Line 1:	P.O. Box 1288		
Address Line 4:	Tampa, FLORIDA 33601-1288		
ATTORNEY DOCKET NUMBER:	90158-9		
NAME OF SUBMITTER:	Karen Lee		
Signature:	/karen lee/		
Date:	01/23/2006		

CH \$40.00 1361351

Total Attachments: 4

source=AdamsLstep3#page1.tif

source=AdamsLstep3#page2.tif

source=AdamsLstep3#page3.tif

source=AdamsLstep3#page4.tif



Office of the Secretary of State

CERTIFICATE OF AMENDMENT OF


Adams Respiratory Therapeutics, Inc.
146025700

[formerly: ADAMS LABORATORIES, INC.]

The undersigned, as Secretary of State of Texas, hereby certifies that the attached Articles of amendment for the above named entity have been received in this office and have been found to conform to law.

ACCORDINGLY the undersigned, as Secretary of State, and by virtue of the authority vested in the Secretary by law hereby issues this Certificate of Amendment.

Dated: 04/18/2005
Effective: 04/18/2005



A handwritten signature in black ink that reads "Roger Williams".

Roger Williams
Secretary of State

ADAMS LABORATORIES, INC.
ARTICLES OF AMENDMENT

FILED
In the Office of the
Secretary of State of Texas

APR 18 2005

To the Secretary of State of
the State of Texas:

Corporations Section

Pursuant to the provisions of Article 4.04 of the Texas Business Corporation Act, the undersigned corporation adopts the following Articles of Amendment:

ARTICLE ONE

The name of the Corporation is Adams Laboratories, Inc., a Texas corporation (the "Corporation").

ARTICLE TWO

The following amendment to the Articles of Incorporation was adopted by the shareholders of the Corporation by written consent dated as of April 18, 2005:

Article I of the Articles of Incorporation is hereby amended and restated to read in its entirety as follows:

"The name of the corporation is Adams Respiratory Therapeutics, Inc."

ARTICLE THREE

By written consent dated as of April 18, 2005:

- (1) The holders of (i) more than 60% of the outstanding shares of the Corporation's Series A Convertible Preferred Stock, par value \$.01 per share (the "Series A Preferred") (ii) more than 50% of the outstanding shares of the Corporation's Series B Convertible Preferred Stock, par value \$.01 per share (the "Series B Preferred") and (iii) more than 50% of the outstanding shares of the Corporation's Series C Convertible Preferred Stock, par value \$.01 per share (the "Series C Preferred") (as required by Section 10 of the amended and restated Statement of Resolution establishing and designating the Series A Preferred, Series B Preferred and Series C Preferred and fixing and determining the relative rights thereof which was filed with the Texas Secretary of State on May 19, 2003 (the "Statement of Resolution")) adopted an amendment to the Statement of Resolution (the "Statement of Resolution Amendment") whereby the Statement of Resolution was amended and restated to read as set forth in Exhibit A.

Subject to the shareholder approval referred to above, the Board of Directors of the Corporation duly adopted the resolutions set forth on Exhibit A by unanimous written consent, dated as of March 21, 2005.

ARTICLE FOUR

The number of shares of all classes and series of capital stock of the Corporation outstanding at the time of the adoption of the foregoing amendments were 59,940,184, consisting of 17,508,366 shares of common stock, \$.01 par value per share (the "Common Stock"), 12,271,333 shares of Series A Preferred (with an aggregate of 18,111,028 votes), 16,345,548 shares of Series B Preferred, and 13,814,937 shares of Series C Preferred.

The number of shares entitled to vote on these Articles of Amendment were the 59,940,184 shares (with an aggregate of 65,779,879 votes) of Common Stock, Series A Preferred, Series B Preferred and Series C Preferred, voting together as a single class.

The only shares entitled to vote on the Statement of Resolution Amendment were the 12,271,333 shares of Series A Preferred (with an aggregate of 18,111,028 votes), 16,345,548 shares of Series B Preferred and 13,814,937 shares of Series C Preferred, each voting as separate classes.


ARTICLE FIVE

The holders of 48,512,358 shares (with an aggregate of 53,996,143 votes) of Common Stock, Series A Preferred, Series B Preferred and Series C Preferred, outstanding and entitled to vote and voting together as a single class have signed a consent in writing adopting these Articles of Amendment in accordance with the provision of Article 9.10A of the Texas Business Corporation Act. No shares of Common Stock, Series A Preferred, Series B Preferred or Series C Preferred voted against or abstained on the adoption of these Articles of Amendment.

The holders of 9,298,904 shares (with an aggregate of 14,782,689 votes) of Series A Preferred, 15,949,910 shares of Series B Preferred and 12,704,586 shares of Series C Preferred outstanding and entitled to vote on the Statement of Resolution Amendment each voting as separate classes have signed a consent in writing adopting the Statement of Resolution Amendment in accordance with the provision of Article 9.10A of the Texas Business Corporation Act and Section 10 of the Statement of Resolution. No shares of Series A Preferred, Series B Preferred or Series C Preferred voted against or abstained on the adoption of the Statement of Resolution Amendment.

IN WITNESS WHEREOF, Adams Laboratories, Inc. has caused this instrument to be executed this 18th day of April, 2005.

ADAMS LABORATORIES, INC.

By: 

Name: Walter E. Riehemann

Title: Vice President & General Counsel